Undeterred Capital

Using immune organoids and AI to design drugs that work in people from the start, delivering safe and effective therapies without the need for traditional clinical trials.

Shinkei Systems uses robotics to enhance fishing and food supply chains, focusing on transparency and quality.

Portal is a career engagement platform that helps students build the skills and relationships necessary for career success, focusing on motivation, networking, and employability.

Curative is a leading healthcare services company that created and launched the first-of-its-kind employer-based health insurance plan, focusing on affordability, engagement, and simplicity.

Index Biosystems is innovating food safety with BioTags®, microscopic barcodes made from inactive baker's yeast that simulate contamination to enhance risk management and predictive modeling in the food industry.

Zoo Design Studio offers an AI-powered CAD software that integrates a conversational agent, Zookeeper, to enhance hardware design workflows through reasoning-driven design and generative AI capabilities.

Newlight is revolutionizing the shipping industry by providing innovative solutions that significantly reduce reliance on fossil fuels through hybrid hydrogen-diesel technology.

Polymath builds core autonomy software for off-highway robots. Their platform helps robotics programs move faster by handling the hardest parts of autonomy, enabling retrofits and OEM integration for various vehicle models.

Circe Biomedical is developing innovative cell technologies and systems for diseases of the liver and pancreas, focusing on bioartificial organs and therapeutic cell systems.

Nanopath has developed deep technological breakthroughs that have the potential to change the molecular diagnostic paradigm. They are commercializing a first-in-class molecular diagnostic platform to enable scalable, point-of-care disease diagnosis.

Vibe Bio is a biotech company that uses AI to fund and support overlooked drug programs, focusing on finding cures for rare and neglected diseases. The company combines AI, capital, and community to accelerate drug development and improve decision-making in biopharma.

Bioscience investor translating grant-funded research into venture-scale companies, with a pipeline centered on engineering biology using robotic cloud labs and computational design for human health and planetary sustainability. The firm grew directly out of a philanthropic grants program at the Thiel Foundation that funded highly speculative science before spinning into a traditional venture fund.

Early-stage investor in advanced tech and healthcare that funds companies with at least one female founder, focusing on STEM startups with female executives.

Invests at seed and early stages in purpose-driven, trailblazing entrepreneurs with unique ideas capable of reinventing entire industries. Focuses on companies founded by mission-driven founders building transformative technologies.

Invests in disruptive, technology-focused startups; established in 1999.

Refactor Capital is a solo GP venture fund where founders get direct access to Zal Bilimoria as the only decision-maker, applying software operator experience from Google, Netflix, and LinkedIn to hard tech sectors like aerospace, synthetic biology, and energy storage. The fund leads seed rounds with $1-2M checks targeting ~10% ownership across unusually broad hard-tech domains, backed by early hits like Solugen and Astranis.